Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cerevel Therapeutics Holdings, Inc.

https://www.cerevel.com

Latest From Cerevel Therapeutics Holdings, Inc.

Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs

Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings. 

Financing Growth

Cerevel Makes Progress, But Karuna Still One To Watch In Schizophrenia

Competition to bring new schizophrenia therapies to market is increasing, with the need to demonstrate side-effect improvements over existing drugs especially important.

Neurology Commercial

BIO 2021 Notebook: Looking Past The Pandemic

News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic. 

Coronavirus COVID-19 FDA

BIO 2021 Notebook: Looking Past The Pandemic

News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic. 

Coronavirus COVID-19 FDA
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Cerevel Therapeutics, LLC
UsernamePublicRestriction

Register